MX2021009690A - Anticuerpo anti-bag2 y metodos de tratamiento del cancer. - Google Patents

Anticuerpo anti-bag2 y metodos de tratamiento del cancer.

Info

Publication number
MX2021009690A
MX2021009690A MX2021009690A MX2021009690A MX2021009690A MX 2021009690 A MX2021009690 A MX 2021009690A MX 2021009690 A MX2021009690 A MX 2021009690A MX 2021009690 A MX2021009690 A MX 2021009690A MX 2021009690 A MX2021009690 A MX 2021009690A
Authority
MX
Mexico
Prior art keywords
antibody
bag2
methods
treating cancer
fragment
Prior art date
Application number
MX2021009690A
Other languages
English (en)
Spanish (es)
Inventor
Seong Jin Kim
Dong Woo Kang
Original Assignee
Medpacto Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from KR1020190016347A external-priority patent/KR102172541B1/ko
Priority claimed from KR1020190016359A external-priority patent/KR102241558B1/ko
Application filed by Medpacto Inc filed Critical Medpacto Inc
Publication of MX2021009690A publication Critical patent/MX2021009690A/es

Links

Classifications

    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57557Immunoassay; Biospecific binding assay; Materials therefor for cancer of other specific parts of the body, e.g. brain
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5758Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854Immunoglobulins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/505Medicinal preparations containing antigens or antibodies comprising antibodies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/505Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507Comprising a combination of two or more separate antibodies
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/20Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565Complementarity determining region [CDR]
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/70Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701Details
    • G01N2333/4703Regulators; Modulating activity

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Plant Pathology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
MX2021009690A 2019-02-12 2020-02-12 Anticuerpo anti-bag2 y metodos de tratamiento del cancer. MX2021009690A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
KR1020190016347A KR102172541B1 (ko) 2019-02-12 2019-02-12 Bag2 항체를 이용한 암 진단용 조성물 및 이를 이용한 방법
KR1020190016359A KR102241558B1 (ko) 2019-02-12 2019-02-12 Bag2 폴리펩티드 또는 이의 단편에 특이적으로 결합하는 항체 또는 그의 항원 결합 단편
PCT/IB2020/051136 WO2020165794A1 (en) 2019-02-12 2020-02-12 Anti-bag2 antibody and methods of treating cancer

Publications (1)

Publication Number Publication Date
MX2021009690A true MX2021009690A (es) 2021-10-01

Family

ID=72044199

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2021009690A MX2021009690A (es) 2019-02-12 2020-02-12 Anticuerpo anti-bag2 y metodos de tratamiento del cancer.

Country Status (11)

Country Link
US (2) US12122822B2 (https=)
EP (2) EP3938788A4 (https=)
JP (4) JP7706154B2 (https=)
CN (2) CN114269779B (https=)
AU (1) AU2020222326B2 (https=)
BR (1) BR112021015940A2 (https=)
CA (1) CA3129748A1 (https=)
MX (1) MX2021009690A (https=)
SG (1) SG11202108140SA (https=)
WO (2) WO2020165797A1 (https=)
ZA (1) ZA202106551B (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112021015940A2 (pt) * 2019-02-12 2021-10-05 Medpacto, Inc. Anticorpo anti-bag2 e métodos de tratamento de câncer

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7560537B2 (en) 2002-09-30 2009-07-14 Ludwig Institute For Cancer Research Human sarcoma-associated antigens
EP1639090A4 (en) 2003-06-09 2008-04-16 Univ Michigan COMPOSITIONS AND METHODS OF TREATMENT AND DIAGNOSIS OF CANCER
JP2008518629A (ja) 2004-11-08 2008-06-05 シェーリング コーポレイション Mdl−1の腫瘍との関連およびその方法
US20060159681A1 (en) * 2004-12-14 2006-07-20 Functional Neuroscience Inc. Compositions and methods to inhibit cell loss by using inhibitors of BAG
EP2142670A1 (en) * 2007-04-05 2010-01-13 Source Precision Medicine, Inc. Gene expression profiling for identification, monitoring, and treatment of breast cancer
CA2713156A1 (en) * 2008-02-04 2009-08-13 Bipar Sciences, Inc. Methods of diagnosing and treating parp-mediated diseases
US20100204055A1 (en) * 2008-12-05 2010-08-12 Bonner-Ferraby Phoebe W Autoantibody detection systems and methods
ITMI20131351A1 (it) 2013-08-07 2015-02-08 Biouniversa Srl Molecole leganti il recettore di bag3 per uso terapeutico.
JP6637290B2 (ja) * 2015-11-05 2020-01-29 武 永安 Ck19に特異的なモノクローナル抗体およびこれを産生するハイブリドーマ、癌の検出キット、癌の検出方法および癌の転移の判定方法
EP3364190A1 (en) * 2017-02-20 2018-08-22 Panka Cancer Research AG Method of detecting cancer or cancer cells
KR102039624B1 (ko) * 2017-03-03 2019-11-01 재단법인 차세대융합기술연구원 BAG2 및 Cathepsin B 상호결합 억제 물질 스크리닝 방법
KR102230314B1 (ko) * 2017-10-24 2021-03-22 주식회사 메드팩토 혈액으로부터 암을 진단하는 방법
BR112021015940A2 (pt) * 2019-02-12 2021-10-05 Medpacto, Inc. Anticorpo anti-bag2 e métodos de tratamento de câncer

Also Published As

Publication number Publication date
JP2022521706A (ja) 2022-04-12
AU2020222326B2 (en) 2026-03-19
JP7747268B2 (ja) 2025-10-01
JP2025071090A (ja) 2025-05-02
CN114269779B (zh) 2025-05-09
EP3938788A4 (en) 2023-01-04
WO2020165794A1 (en) 2020-08-20
JP2022525843A (ja) 2022-05-20
CA3129748A1 (en) 2020-08-20
JP7706154B2 (ja) 2025-07-11
CN114269779A (zh) 2022-04-01
EP3924382A4 (en) 2023-01-04
BR112021015940A2 (pt) 2021-10-05
CN114761803B (zh) 2025-09-05
ZA202106551B (en) 2024-12-18
JP2025071822A (ja) 2025-05-08
US20230183324A1 (en) 2023-06-15
CN114761803A (zh) 2022-07-15
EP3938788A1 (en) 2022-01-19
US20230194534A1 (en) 2023-06-22
US12583915B2 (en) 2026-03-24
WO2020165797A1 (en) 2020-08-20
EP3924382A1 (en) 2021-12-22
AU2020222326A1 (en) 2021-08-19
US12122822B2 (en) 2024-10-22
SG11202108140SA (en) 2021-08-30

Similar Documents

Publication Publication Date Title
CR20200566A (es) Anticuerpos anti-sirpa y metodos de utilización de los mismos
AR119295A1 (es) Moléculas de unión a antígeno ligantes de cea
JOP20220161A1 (ar) جسم مضاد لـ lilrb1 واستخداماته
NI201700015A (es) Tratamientos conjuntos con anticuerpos anti cd40
PH12019502857A1 (en) Il-1 beta binding antibodies for use in treating cancer
PE20161096A1 (es) INHIBICION DIRIGIDA DEL FACTOR DE CRECIMIENTO TRANSFORMADOR ß (TGFß)
EA201891853A1 (ru) Способы лечения или предотвращения атеросклероза путем введения ингибитора angptl3
EP4644427A3 (en) Manabodies and methods of using
MX2021001268A (es) Anticuerpos anti-btn3a y su uso en el tratamiento del cáncer o trastornos infecciosos.
EA202091810A1 (ru) Антитела к b7-h4 и способы их применения
PH12021550332A1 (en) Anti-cd33 antibodies and methods of use thereof
JOP20210166A1 (ar) علاج الصداع الناتج عن فرط استعمال الأدوية باستخدام أجسام مضادة لـcgrp أو أجسام مضادة لـcgrp-r
MY208743A (en) Anti-ms4a4a antibodies and methods of use thereof
EP4653462A3 (en) Anti-pd-1 antibodies, or fragments thereof, for treating hepatitis b
ZA202213434B (en) Anti-lilrb1 antibody and uses thereof
EA201992315A1 (ru) Композиции и способы для лечения рака легкого
EA201891529A1 (ru) Композиции и способы обнаружения и лечения рака яичников
CL2021000585A1 (es) Métodos para tratar la pancreatitis
JOP20210279A1 (ar) طرق لعلاج حالات مصابة بالتهاب المفاصل الصدفي
CO2022010204A2 (es) Anticuerpos contra la integrina alfa 11 beta 1
MX2020003806A (es) Anticuerpos monoclonales de adn que se dirigen a ctla-4 para el tratamiento y prevención del cáncer.
MX2021009690A (es) Anticuerpo anti-bag2 y metodos de tratamiento del cancer.
PH12022551401A1 (en) Antibodies for the treatment of chronic graft versus host disease
WO2020033926A3 (en) Antibodies that bind cd277 and uses thereof
EA202190698A1 (ru) Гуманизированные анти-c5 антитела и их применение